- Home
- ATEN vs TARS Comparison
ATEN vs TARS Comparison
Compare ATEN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEN
- TARS
- Stock Information
- Founded
- ATEN 2004
- TARS 2016
- Country
- ATEN United States
- TARS United States
- Employees
- ATEN N/A
- TARS N/A
- Industry
- ATEN EDP Services
- TARS Medicinal Chemicals and Botanical Products
- Sector
- ATEN Technology
- TARS Health Care
- Exchange
- ATEN Nasdaq
- TARS Nasdaq
- Market Cap
- ATEN 1.4B
- TARS 1.7B
- IPO Year
- ATEN 2014
- TARS 2020
- Fundamental
- Price
- ATEN $18.33
- TARS $39.18
- Analyst Decision
- ATEN Strong Buy
- TARS Strong Buy
- Analyst Count
- ATEN 3
- TARS 7
- Target Price
- ATEN $21.33
- TARS $67.14
- AVG Volume (30 Days)
- ATEN 844.1K
- TARS 625.8K
- Earning Date
- ATEN 08-05-2025
- TARS 08-07-2025
- Dividend Yield
- ATEN 1.27%
- TARS N/A
- EPS Growth
- ATEN 9.85
- TARS N/A
- EPS
- ATEN 0.67
- TARS N/A
- Revenue
- ATEN $267,158,000.00
- TARS $233,674,000.00
- Revenue This Year
- ATEN $9.40
- TARS $122.94
- Revenue Next Year
- ATEN $7.66
- TARS $44.14
- P/E Ratio
- ATEN $27.25
- TARS N/A
- Revenue Growth
- ATEN 4.90
- TARS 449.03
- 52 Week Low
- ATEN $12.27
- TARS $20.08
- 52 Week High
- ATEN $21.90
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- ATEN 46.76
- TARS 39.78
- Support Level
- ATEN $19.19
- TARS $38.52
- Resistance Level
- ATEN $20.28
- TARS $41.72
- Average True Range (ATR)
- ATEN 0.51
- TARS 1.51
- MACD
- ATEN -0.08
- TARS 0.13
- Stochastic Oscillator
- ATEN 32.85
- TARS 19.08
About ATEN A10 Networks Inc.
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.